Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Merck
Mallinckrodt
Boehringer Ingelheim
Moodys

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-9056

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug AZD-9056: Sponsors, patents, clinical trial progress

AZD-9056 is an investigational drug.

There have been 30 clinical trials for AZD-9056. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There is one US patent protecting this investigational drug and seventy-five international patents.

Recent Clinical Trials for AZD-9056
TitleSponsorPhase
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerAstraZenecaPhase 2

See all AZD-9056 clinical trials

Clinical Trial Summary for AZD-9056

Top disease conditions for AZD-9056
Top clinical trial sponsors for AZD-9056

See all AZD-9056 clinical trials

International Patents for AZD-9056

Drugname Country Document Number Estimated Expiration Related US Patent
AZD-9056 Argentina 035325 2019-12-17   Start Trial
AZD-9056 Austria 261933 2019-12-17   Start Trial
AZD-9056 Austria 350364 2019-12-17   Start Trial
AZD-9056 Austria 358117 2019-12-17   Start Trial
AZD-9056 Austria 376994 2019-12-17   Start Trial
AZD-9056 Australia 2005202321 2019-12-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
Moodys
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.